Navigation Links
Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that, following the completion of a Phase 1 clinical trial program for APD597 (JNJ-38431055) under its collaboration with Arena, Ortho-McNeil-Janssen Pharmaceuticals, Inc., has decided not to advance APD597 and has notified Arena that it is terminating the collaboration, effective December 28, 2010. APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, which, along with other compounds and intellectual property, will revert to Arena upon termination of the collaboration. Arena owns a patent portfolio covering a broad array of internally discovered, oral GPR119 agonists, including next generation compounds that were not part of the collaboration.

The Phase 1 program evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597, and included single and multi-ascending studies in healthy volunteers and in subjects with type 2 diabetes. APD597 was well tolerated and showed dose-proportional pharmacokinetics with a half-life of six to seven hours in solution and approximately 13 hours in suspension in healthy volunteers. The Phase 1 program also provided evidence for incretin stimulation (GLP-1, GIP and PYY) and reductions in post-meal glucose increases with APD597 treatment in both overweight and obese non-diabetic volunteers and in subjects with type 2 diabetes. In general, reductions in post-meal glucose increases were greater with APD597 in combination with sitagliptin, a DPP-4 inhibitor, compared to sitagliptin alone.

"Results of the Phase 1 program suggest that APD597 may have utility both alone and in combination with a DPP-4 inhibitor for the treatment of type 2 diabetes," said Jack Lief, Arena's President and Chief Executive Officer. "With our existing GPR119 patent portfolio, internally discovered next generation compounds a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
2. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
3. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
4. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
5. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
6. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
9. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
10. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ANGELES , July 23, 2014  Researchers from ... with calcium elevates calcium levels too high, ... among other health problems. Women close to ... and vitamin D to prevent diseases such as osteoporosis, ... would recommend that women determine how much calcium they ...
(Date:7/23/2014)... BOSTON , July 23, 2014  The ... CBRX ) will hold a conference call ... for the second quarter ended June 30, 2014. ... July 31, 2014Time: , 8:30 am EDTDial-in numbers: ... (Canada) or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... , July 23, 2014  Cardica, Inc. (Nasdaq: ... for its fiscal fourth quarter and year ended June 30, ... Cardica,s management will host a conference call at 4:30 p.m. ... update on the company,s business. Conference Call Details ... at 4:30 p.m. Eastern Time via phone, please dial 866-953-6859 ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
... Evergreen Hospital – one of the region,s leaders in ... gallbladder removal in the Washington and Oregon region on ... a procedure just approved by the FDA. ... two patients – a 66-year-old man and a 33-year-old ...
... March of Dimes announced today that Watson Pharmaceuticals has become ... the March of Dimes number one fundraising event, and will ... the organizations will also work to raise awareness of risk ... participating in March for Babies events around the country as ...
Cached Medicine Technology:Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 2Evergreen Hospital to Perform Region's First Single-Incision Gallbladder Removal 3Watson Partners With March of Dimes to Help Fight Preterm Birth 2
(Date:7/23/2014)... study in East Asian women has identified three genetic ... The research, led by Vanderbilt University investigators, was published ... While breast cancer is one of the most common ... risk factors for the disease have focused on women ... heritage and environmental exposures between East Asian women and ...
(Date:7/23/2014)... July 23, 2014 Five years ago, when ... there were few options for babies diagnosed with a medical ... travel across the country for innovative fetal therapies. Since then, ... Institute to care for their babies in the womb, and ... interventions. , “A number of the babies we see ...
(Date:7/23/2014)... Dennis Thompson HealthDay Reporter , ... with salt is associated with double the risk of heart ... risk skyrockets even higher among those whose diabetes isn,t well-managed, ... people with diabetes who consumed an average of 5.9 grams ... disease than those who consumed, on average, 2.8 grams of ...
(Date:7/23/2014)... San Jose, California (PRWEB) July 23, 2014 ... – Biocompatible materials are biodegradable substances exclusively developed ... to repair or replace diseased body tissues. These ... tissue rejection by the host. Global market for ... driven by factors such as technological advancements and ...
(Date:7/23/2014)... Jose, California (PRWEB) July 23, 2014 ... Packaging plays a vital role in the marketing ... product from damage to influencing customers’ purchase decision. ... brand/product differentiation. Intelligent and efficient packaging provides ample ... to invest in advanced packaging technologies such as ...
Breaking Medicine News(10 mins):Health News:Vanderbilt-led study identifies genes linked to breast cancer in East Asian women 2Health News:St. Louis Fetal Care Institute Marks Five Years of Life Changing Care and Fetal Surgery 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 2Health News:High-Salt Diets Could Double Risk of Heart Woes for Diabetics 3Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Surge in R&D Investments to Drive the Global Biocompatible Materials Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4
... By Randy Dotinga HealthDay Reporter , THURSDAY, ... more evidence that people infected with HIV, the virus that ... as other patients when they undergo kidney transplants. Up ... to HIV patients because of fear that AIDS would quickly ...
... hosting an event on World Aids Day, bringing together some ... future projections for the AIDS pandemic., The panel speakers are ... of Hygiene & Tropical Medicine and former Executive Director of ... Larson, Director of aids2031, an independent consortium set up by ...
... HealthDay Reporter , THURSDAY, Nov. 18 (HealthDay News) ... procedure, can be made more precise by combining a ... Researchers found that a femtosecond laser, used for many ... tissue more cleanly and accurately than manual cataract surgery, ...
... Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- Using the ... that doctors, prescribing patterns vary across the country in response ... Administration. The result is that patients may be ... live, the researchers said. "We were looking at the ...
... a cardiomyopathy about which little is fully understood, is ... according to a study to be presented Nov. 17 ... in Chicago. The researchers also will report that advanced ... to progress over time in patients with LVNC. ...
... international, multi-center study has revealed the discovery of a novel ... form of eye cancer. Researchers have isolated an oncogene called ... than 40 percent of tumor samples taken from patients with ... November 17, 2010 in the New England Journal of ...
Cached Medicine News:Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:AIDS: Taking a long-term view 2Health News:Study Reports More Precise Way to Remove Cataracts 2Health News:Study Reports More Precise Way to Remove Cataracts 3Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3Health News:Cardiac MR sheds light on obscure heart muscle condition 2Health News:Novel genetic mutation that causes the most common form of eye cancer discovered 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: